Keryx Biopharmaceuticals KERX
-
Friday's Bio Pharma Potential Catalyst Price Movers
By Scott Matusow : Catalyst trades in the biopharma sector can provide big profits if traded correctly. Some traders and investors who enjoy bringing more risk into play often times will hold through the catalyst event. While this does bring a lot more risk into play, the reward from engaging in ...
-
The Case For Keryx Biopharmaceuticals' Analyst Upgrade May Be Justified
By VFC : An analyst upgrade last week and renewed investor interest in Keryx Biopharmaceuticals ( KERX ) had shares heavily on the move over the past week, a move initially sparked , in part, by positive Phase III data for Zerenex …
-
Premarket gainers: [[OSUR]] +30%. [[COGO]] +15%. [[SINA]] +12%. [[ABMD]] +9%. [[VELT]] +8%. [[FTR]] +6%. Losers: [[CLNT]] -29%. [[JCP]] -15%. [[TAXI]] -9%. [[NBG]] -8%. [[ANF]] -7%. [[ARNA]] -6%. ...
Premarket gainers: OSUR +30% . COGO +15% . SINA +12% . ABMD +9% . VELT +8% . FTR +6% . Losers: CLNT -29% . JCP -15% . TAXI -9% . NBG -8% . ANF -7% . ARNA -6% . WHX -5% . KERX -5% . Post your comment!
-
6 Low Debt Pharmaceutical Stocks Rated Buy Or Better
By ZetaKap : Interested in pharmaceutical companies? In search of companies that can manage their debt well? Do you prefer companies that can manage their long term debt? Are you after stocks that analysts are calling 'buy' or 'strong buy'? If so, you'll probably like this list. The Debt/Equity ...
-
5 Biotech Stocks At Rock Bottom Price With Takeover Possibility
By StockPandit : So far, 2012 has been the best year for the Biotechnology and Drugs industry. So many stocks have surged in the last four months based on clinical trial results, U.S. Food and Drug Administration (FDA) approval, FDA Advisory Committee's recommendation, European commission approval,
-
Premarket gainers: [[RPRX]] +17%. [[ KERX ]] +13%. [[MNST]] +12%. [[AEG]] +10%. [[NBG]] +9%. [[TSLA]] +8%. [[YONG]] +8%. Losers: [[CDTI]] -14%. [[SGI]] -14%. [[PANL]] -13%. [[QSII]] -10%. [[CSCO]] -8%.
Premarket gainers: RPRX +17% . KERX +13% . MNST +12% . AEG +10% . NBG +9% . TSLA +8% . YONG +8% . Losers: CDTI -14% . SGI -14% . PANL -13% . QSII -10% . CSCO -8% . Post your comment!
-
Keryx Pharmaceuticals ( KERX ) +12.4% premarket, enjoying a boost from two analyst buy recommendations. Ladenburg Thalmann notes data from the long-term Phase 3 study of hyposphatemia drug Zerenex ...
Keryx Pharmaceuticals ( KERX ) +12.4% premarket, enjoying a boost from two analyst buy recommendations ..... Zerenex (data expected in Q4) represents a " significant event " for KERX . Roth Capital raises its target price on the shares to $7 from $4 …
-
5 Biotech Stocks To Buy Now For Gains In 2013
By Cris Frangold : Investors hate to be limited, which is why a selection of choices is always better than just one. It helps to compare companies in the same price range or the same industry because not all good buys are right for everyone. Investing is an individualized science. There are some ...
-
More on Keryx Biopharmaceutical ( KERX ): Q1 misses on a per share basis due to higher R&D expenses, due principally to its KRX-0401 and Zerenex Phase 3 clinical programs. Shares -0.7% AH.
More on Keryx Biopharmaceutical ( KERX ): Q1 misses on a per share basis due to higher R&D expenses, due principally to its KRX-0401 and Zerenex Phase 3 clinical programs. Shares -0.7% AH. Post your comment!
-
Spectrum: A Deeply Undervalued $10 Stock To Buy Now
By ValueMax : Spectrum Pharmaceuticals ( SPPI ) has always been one of my favorite options in the biotech industry and it has lately begun getting attention from some of the experts. The thing people seem to like about this company is its blend of research and development, mixed with a strong plan